Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.70 |
| ▸ | FLT1 | P17948 | 3/20 | 0.65 |
| ▸ | FLT4 | P35916 | 3/20 | 0.65 |
| ▸ | RET | P07949 | 2/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.65 |
| ▸ | KIT | P10721 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | BRAF | P15056 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4548675 | 0.92 | KDR (0.70) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2748210 | 0.89 | KDR (0.67) | KDRFLT1FLT4CYP3A4CYP2D6 | |
| SCHEMBL4548668 | 0.87 | KDR (0.71) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL4548676 | 0.87 | KDR (0.58) | KDRFLT1FLT4CYP3A4CYP2D6 | |
| SCHEMBL4548672 | 0.86 | KDR (0.68) | KDRFLT1FLT4CYP3A4CYP2D6 | |
| SCHEMBL2747747 | 0.84 | KDR (0.69) | KDRFLT1FLT4CYP3A4CYP2D6 | |
| SCHEMBL4548674 | 0.84 | KDR (0.60) | KDRFLT1FLT4CYP3A4CYP2D6 | |
| SCHEMBL4548673 | 0.84 | KDR (0.73) | KDRFLT1FLT4CYP3A4CYP2D6 | |
| SCHEMBL2747967 | 0.83 | BRAF (0.52) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2748104 | 0.82 | KDR (1.00) | KDRFLT1FLT4CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885FLT1 89/4885FLT4 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.